Ipamorelin/CJC-1295 Blend: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 8 sources cited
Overview
The Ipamorelin/CJC-1295 blend combines two complementary GH-releasing peptides in a single vial: Ipamorelin (a GHRP acting on the ghrelin receptor) and CJC-1295 without DAC (a GHRH analog acting on the GHRH receptor). The combination is widely used for GH optimization, and GHRH plus GHRP synergy is documented in men, though no study has measured this blend or its 3 to 5 fold claim.
Mechanism of Action
This blend exploits the well-established GHRH + GHRP synergy. CJC-1295 (no DAC) binds to GHRH receptors on pituitary somatotrophs, priming them for GH release by increasing intracellular cAMP and sensitizing calcium channels. Simultaneously, Ipamorelin activates GHS-R1a receptors through a separate phospholipase C/IP3 pathway, directly triggering GH vesicle exocytosis. Ipamorelin also suppresses somatostatin (GH's natural brake), removing the inhibitory tone that would otherwise limit the GHRH-driven release. The net effect in studies of GHRH given with a GHRP is a markedly amplified pulsatile GH release. Ipamorelin's selectivity for GH over ACTH and cortisol was shown in rats and swine, and has not been measured in people or in this combination.
Ipamorelin/CJC-1295 Blend Benefits: What the Research Shows
- The GHRH + GHRP synergy is documented in humans: co-infusion of GHRH with GHRP-2 produces far more GH than either peptide alone, and the effect shrinks with age and visceral fat (Veldhuis and Bowers, 2009)
- The components are unevenly studied: ipamorelin's selectivity was shown in animals (Raun et al., 1998) and its pharmacokinetics in volunteers, while FDA found no pharmacological or clinical studies of CJC-1295 without DAC
- In the longest trial of a GH secretagogue in older adults, a year of oral MK-677 raised GH and IGF-1 and increased fat-free mass by about 1 kg, with no change in visceral fat, no gain in strength or function, and reduced insulin sensitivity (Nass et al., 2008)
- The synergy is pharmacologically well-understood: convergent signaling on different intracellular pathways in the same somatotroph cell
Ipamorelin/CJC-1295 Blend Dosage
- Standard dose: 100–300 mcg of each peptide (combined in one injection), 1–3 times daily
- Common blend ratios: 1:1 (e.g., 100 mcg Ipamorelin + 100 mcg CJC-1295 per injection)
- Optimal timing: upon waking (fasted), post-workout, and before bed
- Must be administered on an empty stomach — wait 2+ hours after eating, 30 minutes before eating
- Cycle: 8–16 weeks on, 4 weeks off
- Pre-bed dose is highest priority — amplifies the natural nocturnal GH surge during deep sleep
- Subcutaneous injection into abdominal fat preferred
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
Ipamorelin/CJC-1295 Blend Side Effects & Safety
Known Side Effects
- Mild head rush or lightheadedness after injection (especially fasted)
- Mild water retention in first 1–2 weeks
- Injection site reactions
- Tingling/numbness in extremities (GH-mediated paresthesia)
- Vivid dreams and deeper sleep
- CJC-1295 may cause transient facial flushing
Safety Profile
The blend inherits the safety profiles of both individual components. Ipamorelin's selectivity comes from animal studies and its human half-life is about 2 hours; CJC-1295 (no DAC) has never had its half-life measured, though the related D-Ala2 analog of GHRH(1-29) cleared with a half-time of 6.7 minutes in men. Together, they maintain physiological GH regulation through preserved somatostatin feedback. Monitor IGF-1, fasting glucose, and HbA1c every 3–6 months. Same contraindications as individual components: active cancer, uncontrolled diabetes, pituitary tumors, pregnancy. No human study has followed either component for longer than a week, and FDA's 2024 reviews recommended against allowing ipamorelin or any form of CJC-1295 in pharmacy compounding.
What to Expect
Week 1: Improved sleep quality — deeper, more restorative. Mild water retention. Week 2–4: Enhanced recovery, better skin hydration, improved energy. Body composition improvements begin. Weeks 5–8: Measurable fat loss and lean mass gains. Skin quality visibly improved. IGF-1 levels elevated significantly. Weeks 9–16: Peak benefits across all domains. This blend typically produces the most comprehensive GH-optimization results available without exogenous GH. Benefits gradually taper over 4–8 weeks after cycling off.
Common Stacks
BPC-157
BPC-157 benefits from the enhanced GH environment for accelerated tissue healing
Tesamorelin
Can alternate with tesamorelin-based protocols for GHRH variety while maintaining the synergistic approach
AOD-9604
AOD-9604 adds targeted lipolysis to the GH-mediated body composition benefits of the blend
Storage & Handling
Store lyophilized blend at 2–8°C or -20°C. Reconstitute with bacteriostatic water per vendor instructions. Refrigerate reconstituted solution and use within 3–4 weeks. Both peptides are reasonably stable in solution when refrigerated. Protect from light.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Veldhuis JD, Bowers CY. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab. 2009.
- Paulo RC, Cosma M, Soares-Welch C, et al. Gonadal status and body mass index jointly determine growth hormone (GH)-releasing hormone/GH-releasing peptide synergy in healthy men. J Clin Endocrinol Metab. 2008.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998.
- Gobburu JV, Agersø H, Jusko WJ, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999.
- Soule S, King JA, Millar RP. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men. J Clin Endocrinol Metab. 1994.
- FDA Briefing Document, Pharmacy Compounding Advisory Committee: evaluation of five CJC-1295-related bulk drug substances. U.S. Food and Drug Administration. 2024.
- FDA Briefing Document, Pharmacy Compounding Advisory Committee: evaluation of ipamorelin-related bulk drug substances. U.S. Food and Drug Administration. 2024.
- Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008.
Related Peptides
Track Ipamorelin/CJC-1295 Blend in Your Protocol
Log your Ipamorelin/CJC-1295 Blend doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free